|
Sensorineural hearing loss, bilateral
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Dental Pulp Stone
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Periapical bone loss
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Shell teeth
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
DEAFNESS, AUTOSOMAL DOMINANT NONSYNDROMIC SENSORINEURAL 39, WITH DENTINOGENESIS IMPERFECTA 1
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Dentinogenesis imperfecta limited to primary teeth
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Objective:</b> To examine patient preference for treatment with the oral once-weekly dipeptidyl peptidase-4 inhibitor (DPP-4i), trelagliptin, and oral once-daily DPP-4i, alogliptin, administered for 8 weeks each in patients with type 2 diabetes mellitus prescribed a daily DPP-4i.<b>Methods:</b> In this randomized, open-label, two-way crossover study, patients received trelagliptin followed by alogliptin (T-A group) or alogliptin followed by trelagliptin (A-T group), for 8 weeks each (NCT03231709, JapicCTI-173662).
|
31366262 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Objective:</b> To explore persistence and adherence with once-daily, twice-daily, or once-weekly DPP-4 inhibitors (DPP-4i) in Japanese patients with type 2 diabetes.<b>Methods:</b> This retrospective, longitudinal, observational cohort study used data from the Japanese nationwide hospital-based Medical Data Vision (MDV) administrative claims database.
|
31778076 |
2020 |
|
Bullous pemphigoid
|
0.060 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: A significant BP signal was found for DPP-4i.
|
31519110 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> phototherapy indicated that DPP-NF NPs exhibited excellent tumor phototherapeutic efficacy with passive targeting of the tumor site <i>via</i> the enhanced permeability and retention (EPR) effect.
|
30542560 |
2018 |
|
Dentinogenesis imperfecta without osteogenesis imperfecta
|
0.770 |
GeneticVariation
|
disease |
BEFREE |
Dentinogenesis imperfecta 1 (DGI1, MIM 125490) is an autosomal dominant dental disease characterized by abnormal dentin production and mineralization.
|
11175790 |
2001 |
|
Opalescent dentin
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
Dentinogenesis imperfecta 1 (DGI1, MIM 125490) is an autosomal dominant dental disease characterized by abnormal dentin production and mineralization.
|
11175790 |
2001 |
|
Dentinogenesis Imperfecta
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dentinogenesis imperfecta (DI) type II, an inherited disorder affecting dentin, has been linked to mutations in the dentin sialophosphoprotein ( DSPP) gene on chromosome 4q21.
|
14758537 |
2004 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High grade prostatic intraepithelial neoplasia (HGPIN) glands generally displayed DSPP expression levels that were similar to those found in neighboring cancer glands.
|
16108038 |
2006 |
|
Hypoglycemia
|
0.070 |
Biomarker
|
disease |
BEFREE |
Hypoglycemia events per 100 patient-years (costs per event) ranged from 5.4 ($565) in 2007 to 10.4 ($1154) in 2013 for patients starting SU; rates (costs) for patients starting DPP-4i ranged from 3.2 ($308) in 2007 to 6.4 ($482) in 2013.
|
30284688 |
2018 |
|
Dentinogenesis Imperfecta
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dentinogenesis imperfecta type II (DGI1) is an autosomal dominant disorder of dentin formation, which has been mapped to human chromosome 4q12-q21.
|
8586437 |
1995 |
|
Dentinogenesis Imperfecta
|
0.700 |
Biomarker
|
disease |
BEFREE |
Dentin sialoprotein is therefore a candidate for the dentinogenesis imperfecta type II locus.
|
10371252 |
1999 |
|
Dentinogenesis imperfecta without osteogenesis imperfecta
|
0.770 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
DSPP mutation in dentinogenesis imperfecta Shields type II.
|
11175779 |
2001 |
|
Dentinogenesis imperfecta without osteogenesis imperfecta
|
0.770 |
GeneticVariation
|
disease |
BEFREE |
DSPP mutation in dentinogenesis imperfecta Shields type II.
|
11175779 |
2001 |
|
Dentinogenesis imperfecta without osteogenesis imperfecta
|
0.770 |
GeneticVariation
|
disease |
UNIPROT |
DSPP mutation in dentinogenesis imperfecta Shields type II.
|
11175779 |
2001 |
|
Opalescent dentin
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
DSPP mutation in dentinogenesis imperfecta Shields type II.
|
11175779 |
2001 |
|
Dentinogenesis Imperfecta
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dentin phosphoprotein compound mutation in dentin sialophosphoprotein causes dentinogenesis imperfecta type III.
|
15690376 |
2005 |
|
Dentinogenesis Imperfecta
|
0.700 |
Biomarker
|
disease |
CLINGEN |
Dentin phosphoprotein compound mutation in dentin sialophosphoprotein causes dentinogenesis imperfecta type III.
|
15690376 |
2005 |
|
Dentinogenesis Imperfecta
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
DSPP mutations are the principal cause of dentin dysplasia type II, dentinogenesis imperfecta type II, and dentinogenesis imperfecta type III.
|
19026876 |
2008 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
DSPP-silenced OSC2 cells showed altered cell morphology, reduced viability, decreased colony-formation ability, decreased migration and invasion, G0/G1 cell-cycle arrest, and increased tumor cell sensitivity to cisplatin-induced apoptosis.
|
21103065 |
2010 |